July 13, 2016
Spectrum Pharmaceuticals said Wednesday that it had reached a settlement with Fresenius Kabi in a Delaware federal suit accusing it of infringing three patents for its cancer drug Folotyn, after reaching other deals with Teva Pharmaceuticals, Dr. Reddy's and Sandoz.